Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

A cell study linked toxic SOD1 forms to motor neuron-like cell death

Original source

Large SOD1 aggregates, unlike trimeric SOD1, do not impact cell viability in a model of amyotrophic lateral sclerosis.Proc Natl Acad Sci U S A · 16 April 2018 (opens in a new tab)

Compass summarised this from the study's abstract.

Study details

Studied in
Human

Related topics

A study of superoxide dismutase 1 (SOD1) found that a trimeric form damaged motor neuron-like cells, while large fibril-like aggregates did not reduce cell survival. The findings suggest that smaller SOD1 oligomers, rather than mature aggregates, may drive toxicity in this model of amyotrophic lateral sclerosis (ALS).

Why this matters

This helps researchers distinguish potentially harmful SOD1 forms from larger aggregates that may be less toxic or protective. The work was conducted in cells, so it does not show that changing SOD1 aggregates would benefit people with ALS or alter treatment.

Limitations and context

The study used engineered SOD1 mutants and motor neuron-like cells rather than people or an animal model. It addresses a mechanism in SOD1-associated ALS and does not test a treatment or establish that the same effects occur in patients.

Summarised by Compass 16 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Bibliographic data from PubMed is courtesy of the U.S. National Library of Medicine. Compass does not reproduce source abstracts and may not reflect the most current record.

Relevant to you?